Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Projects Update

29 Sep 2008 07:00

RNS Number : 5036E
ViaLogy PLC
29 September 2008
 



ViaLogy Plc ("ViaLogy" or "the Company")

Projects Update

Pasadena, California - 29 September, 2008Vialogy PLC (AIM: VIY), the AiM-listed technology company, is pleased to announce significant developments in three of its major projects. 

Software installation in military base

The Company has been awarded a sub-contract from a major US defense system integrator for the insertion of ViaLogy's sensor interoperability platform software into an operating military base security system. ViaLogy will integrate the multiple perimeter surveillance systems on the base, simplifying operations and eliminating system failure in security deployment. 

More detailed information on the project and the names of the systems integrator firm and the specific military base cannot be disclosed for national security reasons.

In addition, SPM® was recently deployed by Los Angeles County first responders at a major sports event attended by over 90,000 fans to demonstrate and assess effectiveness in providing advance warning and crisis management in the event of a chemical or biological terrorist event. Following this success, LA County also deployed SPM to co-ordinate security and surveillance at the 60th Emmy Awards ceremony in Los Angeles. 

"The diversity of these SPM applications helps to position the product as the certified CBRNE (Chemical, Biological, Radiological, Nuclear and Explosive detection) and physical security sensor integration engine for purchases of enterprise-grade systems. We anticipate future customers will include state, local and federal procurement agencies, including the Department of Homeland Security, and system integrator firms", said Terry Bond, ViaLogy's Chairman.

New dates set for Oil & Gas validation

Hurricane Ike has caused a brief postponement of the ViaLogy-Atascosa Engineering partnership plans to drill its first well and thereby prove the value of ViaLogy's Quantum Resonance Interferometry (QRI™) technology which is being used to determine the oil reservoir's location, capacity and porosity, as well as the exact drill site. This adaptation of QRI is branded QuantumRD.

"Ike's unpredictable progress through Texas meant we had to delay preparations for erecting the drilling equipment", said Mr. Bond. "At one point it appeared that the site, near San Antonio, would be in the eye of the storm. Fortunately it transpired the area was on the perimeter and we sustained minimal damage."

While the project is a pilot, this is a fully operational extraction site and a strike should substantiate the effectiveness of the technology in the oil discovery process. Drilling is now scheduled for mid-October and results will be available towards the end of that month.

Aerial pipeline surveys in October

The second imminent application for QRI, called QSUB™, will be used to determine exact geolocation and condition of underground oil and gas pipelines. Proof-of-concept flights by Sky Research Inc of Ashland, Oregon, www.skyresearch.com, organised by ViaLogy and its partner firm ASTFS, are scheduled for this October. The aim is for QSUB technology to analyse data from airborne synthetic aperture radar (SAR) and light detection and ranging (LIDAR) sensors. ViaLogy has received strong indications of interest from leading pipeline firms in the success of the proof-of-concept work and in purchase of the operational service when available.

"There are almost 3 million kilometres of buried pipeline in the US alone", said Mr. Bond. "A cost-effective means of providing exact pipeline location and status is in high demand by both pipeline firms and regulatory agencies. We believe that the latest radar equipment, combined with QSUB data analysis will enable this to be done by aerial surveys."

Ends

Further information from:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Nominated Advisor (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000

Stockbroker - St. Helen's Capital PLC +44 (0) 20-7628 5582 

PR Consultants - Redleaf Communications 

Emma Kane / Samantha Robbins +44 (0) 20-7822-0200 

About ViaLogy: 

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. Vialogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.vialogy.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESBRGDCLDDGGII
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.